Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung Cancer
The purpose of this phase 1b/2 study is to estimate the treatment effect of study drug measuring progression free survival.
Non Small Cell Lung Cancer
DRUG: AMG 386|DRUG: AMG 386|DRUG: AMG 386 Placebo|DRUG: Pemetrexed|DRUG: Carboplatin
Progression Free Survival, Subjects will be evaluated for progression free survival., Incidence of adverse events and clinical laboratory abnormalities defined as a DLT
To evaluate the incidence of adverse events and clinical laboratory abnormalities defined as dose-limiting toxicity in subjects with metastatic non-squamous non-small cell lung cancer (NSCLC) treated with AMG 386 in combination with pemetrexed and carboplatin